Pharmaceutical companies systematically misuse the concept of “innovation” to justify extending patent monopolies on existing drugs, often without meaningful therapeutic advances, according to a new analysis examining industry practices and regulatory failures.
Patent thickets block generic drug competition
Number of patents filed on blockbuster drugs to extend monopolies
Source: Patent analysis by Tahir Amin, Initiative for Medicines | Georgian Medical Journal News
The mechanics of manufactured innovation
According to Tahir Amin and Rohit Malpani in their book “Pharma Monopoly,” pharmaceutical companies have transformed the patent system into a tool for evergreening—extending monopolies through minor modifications rather than genuine innovation. The authors document how AbbVie filed 247 patents on Humira, its arthritis drug, to maintain market exclusivity long after the original patent expired.
“Just because a company invests does not mean it has invented anything novel,” write the authors, challenging the industry’s core justification for extended patent protection. This strategy has profound implications for healthcare policy and patient access to affordable medications.
Regulatory capture enables evergreening strategies
The analysis reveals how patent offices approve applications for minor changes—such as new dosing schedules, delivery mechanisms, or combinations with existing drugs—that provide little therapeutic benefit. The US Patent and Trademark Office grants patents on modifications like changing a twice-daily pill to once-daily, enabling companies to reset their exclusivity periods.
European regulators face similar challenges, with the European Patent Office approving thousands of pharmaceutical patents annually, many representing incremental modifications rather than breakthrough therapies. These practices directly impact global health equity, particularly in low- and middle-income countries where patients cannot afford branded medications.
Economic impact extends beyond individual drugs
The evergreening phenomenon affects entire therapeutic classes, with companies strategically timing patent applications to maintain market dominance. Research published in the Journal of Health Economics demonstrates that delayed generic entry costs healthcare systems billions annually in unnecessary drug spending.
For countries like Georgia implementing universal health coverage, these practices pose significant challenges to healthcare sustainability. The Georgian government’s efforts to expand access to essential medicines face obstacles when international pharmaceutical companies maintain artificial monopolies through patent thickets.
AbbVie generated over $200 billion in Humira sales through patent extensions that added no meaningful therapeutic value, demonstrating how innovation rhetoric masks profit-driven monopoly strategies.
— Tahir Amin, Initiative for Medicines, Access to Health (Pharma Monopoly, 2024)
Key takeaways
- Patent thickets allow companies to extend monopolies for decades beyond original patent expiration dates
- Minor modifications receive patent protection despite lacking therapeutic innovation or patient benefit
- Regulatory agencies approve evergreening applications that prioritize corporate profits over public health
Frequently asked questions
How do patent thickets prevent generic competition?
Companies file hundreds of patents on minor modifications to create legal barriers that generic manufacturers must navigate. Each patent requires separate challenges in court, making generic entry financially prohibitive and legally complex.
What qualifies as genuine pharmaceutical innovation?
True innovation involves new mechanisms of action, treatments for previously untreatable conditions, or significant improvements in safety or efficacy. Minor changes like new pill coatings or delivery devices typically do not meet this threshold.
Can regulatory reforms address evergreening practices?
Several proposals include raising patent standards, limiting secondary patents, and implementing automatic generic substitution. However, pharmaceutical industry lobbying and complex international trade agreements create significant implementation challenges.
The pharmaceutical industry’s manipulation of innovation narratives represents a fundamental challenge to global health equity and healthcare sustainability. As healthcare systems worldwide grapple with rising costs, addressing patent evergreening becomes essential for ensuring patient access to life-saving medications. Policymakers must distinguish between genuine therapeutic advances and profit-driven patent strategies that exploit regulatory weaknesses.
Source: Opinion: The innovation trap: How pharma weaponizes a word to extend monopolies
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
